Role of BET Bromodomain in Hematopoietic Differentiation from hESCs

Zi Cen Feng; Yu Qi Wen; Meng Ge Wang; Qian Tu; Hong Tao Wang; Zack Z. Wang; Jia Xi Zhou

doi:10.7534/j.issn.1009-2137.2018.04.040

Role of BET Bromodomain in Hematopoietic Differentiation from hESCs

Zi Cen Feng, Yu Qi Wen, Meng Ge Wang, Qian Tu, Hong Tao Wang, Zack Z. Wang, Jia Xi Zhou

Research output: Contribution to journal › Article › peer-review

Abstract

OBJECTIVE: To explore the role of bromodomain and extra terminal (BET) bromodomain in hematopoietic differentiation from human enbryonic stem cells (hESC). METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages. RESULTS: The analysis results of immunofluorescence, flow cytometry and real-time PCR showed that I-BET 151 significantly inhibited the generation of CD43 positive hematopoietic stem and progenitor cells (HSPCs). It was found that the addition of I-BET 151 in different stages, including APLNR+ lateral plate mesoderm production, CD34+CD31+ hemogenic endothelium (HEP) generation and endothelial-to-hematopoietic transition, significantly suppressed the generation of CD43 positive hematopoietic progenitor cells. CONCLUSION: I-BET 151 inhibites hematopoietic differentiation from hESCs at several stages, suggesting that the BET bromodomain plays important roles in multiple stages of hematopoietic differentiation from hESCs.

Original language	English (US)
Pages (from-to)	1186-1193
Number of pages	8
Journal	Zhongguo shi yan xue ye xue za zhi
Volume	26
Issue number	4
DOIs	https://doi.org/10.7534/j.issn.1009-2137.2018.04.040
State	Published - Aug 1 2018
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.7534/j.issn.1009-2137.2018.04.040

Cite this

@article{cb8577926c1441e989cce6cef4cfb4d6,

title = "Role of BET Bromodomain in Hematopoietic Differentiation from hESCs",

abstract = "OBJECTIVE: To explore the role of bromodomain and extra terminal (BET) bromodomain in hematopoietic differentiation from human enbryonic stem cells (hESC). METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages. RESULTS: The analysis results of immunofluorescence, flow cytometry and real-time PCR showed that I-BET 151 significantly inhibited the generation of CD43 positive hematopoietic stem and progenitor cells (HSPCs). It was found that the addition of I-BET 151 in different stages, including APLNR+ lateral plate mesoderm production, CD34+CD31+ hemogenic endothelium (HEP) generation and endothelial-to-hematopoietic transition, significantly suppressed the generation of CD43 positive hematopoietic progenitor cells. CONCLUSION: I-BET 151 inhibites hematopoietic differentiation from hESCs at several stages, suggesting that the BET bromodomain plays important roles in multiple stages of hematopoietic differentiation from hESCs.",

author = "Feng, {Zi Cen} and Wen, {Yu Qi} and Wang, {Meng Ge} and Qian Tu and Wang, {Hong Tao} and Wang, {Zack Z.} and Zhou, {Jia Xi}",

year = "2018",

month = aug,

day = "1",

doi = "10.7534/j.issn.1009-2137.2018.04.040",

language = "English (US)",

volume = "26",

pages = "1186--1193",

journal = "Zhongguo shi yan xue ye xue za zhi",

issn = "1009-2137",

publisher = "Haidian-qu",

number = "4",

}

TY - JOUR

T1 - Role of BET Bromodomain in Hematopoietic Differentiation from hESCs

AU - Feng, Zi Cen

AU - Wen, Yu Qi

AU - Wang, Meng Ge

AU - Tu, Qian

AU - Wang, Hong Tao

AU - Wang, Zack Z.

AU - Zhou, Jia Xi

PY - 2018/8/1

Y1 - 2018/8/1

N2 - OBJECTIVE: To explore the role of bromodomain and extra terminal (BET) bromodomain in hematopoietic differentiation from human enbryonic stem cells (hESC). METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages. RESULTS: The analysis results of immunofluorescence, flow cytometry and real-time PCR showed that I-BET 151 significantly inhibited the generation of CD43 positive hematopoietic stem and progenitor cells (HSPCs). It was found that the addition of I-BET 151 in different stages, including APLNR+ lateral plate mesoderm production, CD34+CD31+ hemogenic endothelium (HEP) generation and endothelial-to-hematopoietic transition, significantly suppressed the generation of CD43 positive hematopoietic progenitor cells. CONCLUSION: I-BET 151 inhibites hematopoietic differentiation from hESCs at several stages, suggesting that the BET bromodomain plays important roles in multiple stages of hematopoietic differentiation from hESCs.

AB - OBJECTIVE: To explore the role of bromodomain and extra terminal (BET) bromodomain in hematopoietic differentiation from human enbryonic stem cells (hESC). METHODS: The effect of BET hematopoietic inhibitor I-BET151 on hematopoietic differentiation from hESC was detected by using a monolayer hematopoietic defferentiation model, immunofluorescence, flow cytometry and real-time PCR; moreover the role of I-BET151 in process of hematopoietic differentiation was explored by adding I-BET151 in different differentiation stages. RESULTS: The analysis results of immunofluorescence, flow cytometry and real-time PCR showed that I-BET 151 significantly inhibited the generation of CD43 positive hematopoietic stem and progenitor cells (HSPCs). It was found that the addition of I-BET 151 in different stages, including APLNR+ lateral plate mesoderm production, CD34+CD31+ hemogenic endothelium (HEP) generation and endothelial-to-hematopoietic transition, significantly suppressed the generation of CD43 positive hematopoietic progenitor cells. CONCLUSION: I-BET 151 inhibites hematopoietic differentiation from hESCs at several stages, suggesting that the BET bromodomain plays important roles in multiple stages of hematopoietic differentiation from hESCs.

UR - http://www.scopus.com/inward/record.url?scp=85056555354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056555354&partnerID=8YFLogxK

U2 - 10.7534/j.issn.1009-2137.2018.04.040

DO - 10.7534/j.issn.1009-2137.2018.04.040

M3 - Article

C2 - 30111428

AN - SCOPUS:85056555354

SN - 1009-2137

VL - 26

SP - 1186

EP - 1193

JO - Zhongguo shi yan xue ye xue za zhi

JF - Zhongguo shi yan xue ye xue za zhi

IS - 4

ER -

Role of BET Bromodomain in Hematopoietic Differentiation from hESCs

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this